{"id":"pirarubicin","rwe":[{"pmid":"41872646","year":"2026","title":"Mechanistic Insights into pH-Responsive Drug Release and Antitumor Effects of an Albumin-Pirarubicin Conjugate.","finding":"","journal":"Pharmaceutical research","studyType":"Clinical Study"},{"pmid":"41839262","year":"2026","title":"Squid tentacle-mimetic magnetically targeted nanomotors to overcome the bladder barrier for synergistic chemotherapy-immunotherapy of bladder cancer.","finding":"","journal":"Journal of controlled release : official journal of the Controlled Release Society","studyType":"Clinical Study"},{"pmid":"41772163","year":"2026","title":"The effects of low-dose X-ray pre-irradiation followed by 4-hydroxybenzoic acid and vanillic acid on P-glycoprotein-mediated efflux pirarubicin in multidrug-resistant K562/Dox cells.","finding":"","journal":"Naunyn-Schmiedeberg's archives of pharmacology","studyType":"Clinical Study"},{"pmid":"41698628","year":"2026","title":"Intravesical hematoporphyrin photodynamic therapy combined with pirarubicin for intermediate and high-risk non-muscle-invasive bladder cancer: A multicenter, prospective single-arm cohort.","finding":"","journal":"Photodiagnosis and photodynamic therapy","studyType":"Clinical Study"},{"pmid":"41668835","year":"2026","title":"B-Cell Lymphoma Following an Indolent Course Over 30 Years with Immunophenotypic Changes at Each Recurrence.","finding":"","journal":"European journal of case reports in internal medicine","studyType":"Clinical Study"}],"tags":[{"label":"pirarubicin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L01DB08","category":"atc"},{"label":"Active","category":"status"},{"label":"Antineoplastic Agents","category":"pharmacology"}],"phase":"phase_3","safety":{"safetySignals":[{"llr":263.542,"date":"","count":74,"signal":"Bone marrow failure","source":"DrugCentral FAERS","actionTaken":"Reported 74 times (LLR=264)"},{"llr":169.081,"date":"","count":49,"signal":"Myelosuppression","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=169)"},{"llr":53.034,"date":"","count":9,"signal":"Renal salt-wasting syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=53)"},{"llr":49.429,"date":"","count":35,"signal":"Febrile neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=49)"},{"llr":47.528,"date":"","count":7,"signal":"Pleuroparenchymal fibroelastosis","source":"DrugCentral FAERS","actionTaken":"Reported 7 times (LLR=48)"},{"llr":42.406,"date":"","count":6,"signal":"Cerebral salt-wasting syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 6 times (LLR=42)"}],"commonSideEffects":[{"effect":"Bone marrow failure","drugRate":"LLR 264","severity":"common"},{"effect":"Myelosuppression","drugRate":"LLR 169","severity":"common"},{"effect":"Renal salt-wasting syndrome","drugRate":"LLR 53","severity":"common"},{"effect":"Febrile neutropenia","drugRate":"LLR 49","severity":"common"},{"effect":"Pleuroparenchymal fibroelastosis","drugRate":"LLR 48","severity":"common"},{"effect":"Cerebral salt-wasting syndrome","drugRate":"LLR 42","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"pinorubicin","offLabel":[],"synonyms":["pirarubicin","pinorubicin","therarubicin"],"timeline":[],"approvals":[],"brandName":"Pinorubicin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"pirarubicin","explanation":"Imagine DNA as a ladder with rungs that need to be opened and closed for the cell to divide. Pirarubicin gets in the way of this process by inserting itself between the rungs, causing the cell to become confused and eventually die. This helps to slow or stop the growth of cancer cells.","oneSentence":"Pirarubicin works by intercalating DNA strands, thereby inhibiting the progression of the enzyme topoisomerase II and inducing DNA damage in cancer cells.","technicalDetail":"Pirarubicin exerts its antineoplastic effects by forming a complex with DNA, which inhibits the activity of topoisomerase II, a crucial enzyme involved in DNA replication and transcription."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2198","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=PIRARUBICIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PIRARUBICIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:21:06.236933","biosimilars":[],"competitors":[{"drugName":"doxorubicin","drugSlug":"doxorubicin","fdaApproval":"1974-08-07","genericCount":24,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"daunorubicin","drugSlug":"daunorubicin","fdaApproval":"1979-12-19","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"epirubicin","drugSlug":"epirubicin","fdaApproval":"1999-09-15","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"idarubicin","drugSlug":"idarubicin","fdaApproval":"1990-09-27","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mitoxantrone","drugSlug":"mitoxantrone","fdaApproval":"1987-12-23","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"valrubicin","drugSlug":"valrubicin","fdaApproval":"1998-09-25","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"pirarubicin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"doxorubicin","brandName":"doxorubicin","genericName":"doxorubicin","approvalYear":"1974","relationship":"same-class"},{"drugId":"daunorubicin","brandName":"daunorubicin","genericName":"daunorubicin","approvalYear":"1979","relationship":"same-class"},{"drugId":"epirubicin","brandName":"epirubicin","genericName":"epirubicin","approvalYear":"1999","relationship":"same-class"},{"drugId":"idarubicin","brandName":"idarubicin","genericName":"idarubicin","approvalYear":"1990","relationship":"same-class"},{"drugId":"mitoxantrone","brandName":"mitoxantrone","genericName":"mitoxantrone","approvalYear":"1987","relationship":"same-class"},{"drugId":"valrubicin","brandName":"valrubicin","genericName":"valrubicin","approvalYear":"1998","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07424287","phase":"PHASE3","title":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":["NMIBC"],"enrollment":236,"completionDate":"2030-06"},{"nctId":"NCT07410234","phase":"PHASE2","title":"Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-21","conditions":["Breast Cancer"],"enrollment":110,"completionDate":"2029-02-21"},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":["Breast Cancer"],"enrollment":80,"completionDate":"2029-12-31"},{"nctId":"NCT02435953","phase":"PHASE3","title":"TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Ming Zhao","startDate":"2015-02","conditions":["Hepatocellular Carcinoma","Chemoembolization, Therapeutic","Ablation Techniques, RFA"],"enrollment":242,"completionDate":"2025-10"},{"nctId":"NCT07178171","phase":"PHASE1","title":"A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-11-06","conditions":["TNBC, Triple Negative Breast Cancer"],"enrollment":30,"completionDate":"2030-08-01"},{"nctId":"NCT07100405","phase":"","title":"TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-08-15","conditions":["Hepatocellular Carcinoma"],"enrollment":50,"completionDate":"2028-08-01"},{"nctId":"NCT06740370","phase":"NA","title":"TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-12-13","conditions":["Hepatocellular Carcinoma","Transcatheter Arterial Chemoembolization","Anti-PD1 Antibody","Lenvatinib"],"enrollment":32,"completionDate":"2026-08-30"},{"nctId":"NCT06904183","phase":"PHASE2","title":"Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-04-01","conditions":["Hepatocellular Carcinoma Non-resectable"],"enrollment":320,"completionDate":"2030-03-31"},{"nctId":"NCT06933394","phase":"PHASE2","title":"Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-05-01","conditions":["Neuroblastoma"],"enrollment":92,"completionDate":"2031-05-01"},{"nctId":"NCT06898398","phase":"","title":"TACE Combined Surgery for the Resectable Huge HCC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-01-01","conditions":["Hepatocellular Carcinoma","Hepatic Chemotherapy","Liver Cancer","Surgery"],"enrollment":326,"completionDate":"2025-12-30"},{"nctId":"NCT04297280","phase":"PHASE2","title":"TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Fudan University","startDate":"2020-04-29","conditions":["Hepatocellular Carcinoma"],"enrollment":25,"completionDate":"2025-02-25"},{"nctId":"NCT06397235","phase":"PHASE2","title":"DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-05-01","conditions":["Hepatocellular Carcinoma Non-resectable"],"enrollment":130,"completionDate":"2028-04-30"},{"nctId":"NCT06492395","phase":"PHASE3","title":"Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-08-01","conditions":["Hepatocellular Carcinoma Non-resectable"],"enrollment":178,"completionDate":"2027-07-31"},{"nctId":"NCT06714383","phase":"PHASE2","title":"Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-11-13","conditions":["Osteosarcoma"],"enrollment":50,"completionDate":"2025-11"},{"nctId":"NCT06609850","phase":"NA","title":"The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-01","conditions":["Recurrent Hepatocellular Carcinoma","Lenvatinib","Local Therapy","Ablation","Systemic Therapy"],"enrollment":116,"completionDate":"2028-10-30"},{"nctId":"NCT04954794","phase":"PHASE2","title":"TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2021-07-14","conditions":["Hepatocellular Carcinoma"],"enrollment":29,"completionDate":"2024-04-29"},{"nctId":"NCT05103007","phase":"NA","title":"PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2021-12-01","conditions":["Hepatocellular Carcinoma"],"enrollment":200,"completionDate":"2025-06-30"},{"nctId":"NCT05975151","phase":"PHASE2","title":"Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-10-01","conditions":["Bladder Cancer"],"enrollment":63,"completionDate":"2025-12-01"},{"nctId":"NCT05263219","phase":"PHASE3","title":"DEB-TACE+HAIC vs. HAIC for Large HCC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2022-02-10","conditions":["Unresectable Hepatocellular Carcinoma"],"enrollment":230,"completionDate":"2026-02-09"},{"nctId":"NCT02396043","phase":"PHASE2","title":"Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-03","conditions":["Lymphoma, Lymphoblastic"],"enrollment":50,"completionDate":"2025-03"},{"nctId":"NCT05527912","phase":"PHASE2","title":"A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-02-24","conditions":["Double Express Diffuse Large B-cell Lymphoma"],"enrollment":45,"completionDate":"2024-12-01"},{"nctId":"NCT05582278","phase":"PHASE2","title":"HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC","status":"UNKNOWN","sponsor":"Wen Li","startDate":"2021-01-01","conditions":["Unresectable Hepatocellular Carcinoma"],"enrollment":60,"completionDate":"2024-01-01"},{"nctId":"NCT05558722","phase":"PHASE2","title":"Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2022-11-30","conditions":["Breast Cancer Stage II"],"enrollment":30,"completionDate":"2025-07-30"},{"nctId":"NCT05287308","phase":"NA","title":"Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study","status":"NOT_YET_RECRUITING","sponsor":"Chinese Academy of Medical Sciences","startDate":"2022-03","conditions":["Breast Cancer"],"enrollment":500,"completionDate":"2027-09"},{"nctId":"NCT04437160","phase":"PHASE2","title":"Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences","startDate":"2020-02-01","conditions":["Triple Negative Breast Cancer"],"enrollment":286,"completionDate":"2027-12"},{"nctId":"NCT03342300","phase":"PHASE2,PHASE3","title":"Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma","status":"WITHDRAWN","sponsor":"Peking University People's Hospital","startDate":"2017-11-06","conditions":["Progression-free Survival","Overall Survival","Toxicity"],"enrollment":0,"completionDate":"2020-12-30"},{"nctId":"NCT03121833","phase":"PHASE2","title":"Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2017-05-01","conditions":["Soft Tissue Sarcoma, Adult, Stage IIB"],"enrollment":52,"completionDate":"2019-12-20"},{"nctId":"NCT04126811","phase":"PHASE2","title":"Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-06-01","conditions":["Soft Tissue Sarcoma"],"enrollment":120,"completionDate":"2020-12-31"},{"nctId":"NCT03030157","phase":"PHASE2","title":"Single Versus Long-term Intravesical Instillation Chemotherapy for Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-01","conditions":["Intravesical Instillation"],"enrollment":220,"completionDate":"2020-01"},{"nctId":"NCT02584556","phase":"PHASE2,PHASE3","title":"Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma","status":"WITHDRAWN","sponsor":"Guangxi Medical University","startDate":"2015-10","conditions":["Hepatocellular Carcinoma"],"enrollment":0,"completionDate":"2017-10"},{"nctId":"NCT02585479","phase":"PHASE2,PHASE3","title":"Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma","status":"WITHDRAWN","sponsor":"Guangxi Medical University","startDate":"2015-10","conditions":["Hepatocellular Carcinoma"],"enrollment":0,"completionDate":"2017-10"},{"nctId":"NCT03277716","phase":"NA","title":"Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge","status":"UNKNOWN","sponsor":"Fan Weijun","startDate":"2017-12-01","conditions":["Hepatocellular Carcinoma Non-resectable","Transarterial Chemoembolization","Microwave Ablation"],"enrollment":100,"completionDate":"2021-12-30"},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":["Breast Cancer Organoids"],"enrollment":300,"completionDate":"2021-12-15"},{"nctId":"NCT03892330","phase":"PHASE4","title":"Combination Therapy of Anthracyclines for Children With Nephroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Shengjing Hospital","startDate":"2019-06-01","conditions":["0.5-14 Year Old Children With Nephroblastoma"],"enrollment":120,"completionDate":"2045-06-30"},{"nctId":"NCT02953184","phase":"PHASE2","title":"Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Jilin University","startDate":"2016-11","conditions":["Antineoplastic Combined Chemotherapy Protocols"],"enrollment":160,"completionDate":"2020-11"},{"nctId":"NCT01746992","phase":"PHASE4","title":"CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2012-09","conditions":["ALK-negative Anaplastic Large Cell Lymphoma","Peripherial T Cell Lymphoma,Not Otherwise Specified","Angioimmunoblastic T Cell Lymphoma","Enteropathy Associated T Cell Lymphoma","Hepatosplenic T Cell Lymphoma","Subcutaneous Panniculitis Like T Cell Lymphoma"],"enrollment":200,"completionDate":"2018-12"},{"nctId":"NCT02760953","phase":"NA","title":"TURBt With Adjuvant Cryoablation to Treat Bladder Cancer","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2017-10-19","conditions":["Urinary Bladder Neoplasms"],"enrollment":150,"completionDate":"2018-12-31"},{"nctId":"NCT02740426","phase":"PHASE2","title":"Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2016-08","conditions":["Upper Tract Urothelial Carcinoma","Bladder Recurrence"],"enrollment":200,"completionDate":"2022-05"},{"nctId":"NCT02956772","phase":"PHASE2","title":"Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients","status":"UNKNOWN","sponsor":"Hunan Provincial People's Hospital","startDate":"2016-11","conditions":["Primary Hepatocellular Carcinoma"],"enrollment":190,"completionDate":"2020-11"},{"nctId":"NCT02923557","phase":"PHASE2","title":"Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2016-11","conditions":["Bladder Recurrence","Upper Tract Urothelial Carcinoma","Nephroureterectomy"],"enrollment":200,"completionDate":""},{"nctId":"NCT02903524","phase":"PHASE4","title":"Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2016-09","conditions":["Breast Cancer"],"enrollment":300,"completionDate":"2018-12"},{"nctId":"NCT02838225","phase":"PHASE2","title":"DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2009-01","conditions":["Breast Cancer"],"enrollment":300,"completionDate":""},{"nctId":"NCT02755311","phase":"PHASE3","title":"Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2014-03","conditions":["Hepatocellular Carcinoma"],"enrollment":198,"completionDate":"2016-06"},{"nctId":"NCT02301091","phase":"PHASE3","title":"Combine TACE and RFA Versus TACE Alone for HCC With PVTT","status":"UNKNOWN","sponsor":"Ming Zhao","startDate":"2014-10","conditions":["Hepatocellular Carcinoma"],"enrollment":240,"completionDate":"2019-10"},{"nctId":"NCT02724358","phase":"NA","title":"Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1","status":"COMPLETED","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2012-12","conditions":["Hepatocellular Carcinoma","TACE","Notch1","Rg3"],"enrollment":320,"completionDate":"2015-12"},{"nctId":"NCT02525952","phase":"NA","title":"Treatment for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System","status":"UNKNOWN","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2015-10","conditions":["Hepatocellular Carcinoma"],"enrollment":320,"completionDate":"2017-12"},{"nctId":"NCT02613026","phase":"PHASE3","title":"Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer","status":"COMPLETED","sponsor":"307 Hospital of PLA","startDate":"2009-07","conditions":["Breast Neoplasms"],"enrollment":104,"completionDate":"2015-02"},{"nctId":"NCT01430013","phase":"PHASE2","title":"Trial of Endostar Combined With CHOPT for T Cell Lymphoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2011-06","conditions":["T Cell Lymphoma"],"enrollment":30,"completionDate":"2015-12"},{"nctId":"NCT02547350","phase":"PHASE2","title":"Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas","status":"UNKNOWN","sponsor":"Xuesong Li","startDate":"2015-09","conditions":["Upper Tract Urothelial Carcinoma","Bladder Recurrence"],"enrollment":200,"completionDate":""},{"nctId":"NCT01249690","phase":"PHASE4","title":"Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma","status":"UNKNOWN","sponsor":"Second Military Medical University","startDate":"2010-06","conditions":["Multiple Myeloma"],"enrollment":100,"completionDate":"2014-06"},{"nctId":"NCT00131053","phase":"PHASE2","title":"Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)","status":"UNKNOWN","sponsor":"Japan Adult Leukemia Study Group","startDate":"2002-09","conditions":["Lymphoblastic Leukemia, Acute"],"enrollment":120,"completionDate":"2011-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005780","UNII":"D58G680W0G","CHEBI":"CHEBI:32011","INN_ID":"5877","RXNORM":"33764","UMLSCUI":"C0071126","ChEMBL_ID":"CHEMBL2354444","KEGG_DRUG":"D01885","DRUGBANK_ID":"DB11616","PUBCHEM_CID":"11296583","SNOMEDCT_US":"713434008","MESH_SUPPLEMENTAL_RECORD_UI":"C027260"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"11.1 hours","clearance":"57.7 mL/min/kg","volumeOfDistribution":"43.2 L/kg"},"publicationCount":901,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01DB08","allCodes":["L01DB08"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 23","pmid":"41872646","title":"Mechanistic Insights into pH-Responsive Drug Release and Antitumor Effects of an Albumin-Pirarubicin Conjugate.","journal":"Pharmaceutical research"},{"date":"2026 Mar 14","pmid":"41839262","title":"Squid tentacle-mimetic magnetically targeted nanomotors to overcome the bladder barrier for synergistic chemotherapy-immunotherapy of bladder cancer.","journal":"Journal of controlled release : official journal of the Controlled Release Society"},{"date":"2026 Mar 3","pmid":"41772163","title":"The effects of low-dose X-ray pre-irradiation followed by 4-hydroxybenzoic acid and vanillic acid on P-glycoprotein-mediated efflux pirarubicin in multidrug-resistant K562/Dox cells.","journal":"Naunyn-Schmiedeberg's archives of pharmacology"},{"date":"2026 Feb 14","pmid":"41698628","title":"Intravesical hematoporphyrin photodynamic therapy combined with pirarubicin for intermediate and high-risk non-muscle-invasive bladder cancer: A multicenter, prospective single-arm cohort.","journal":"Photodiagnosis and photodynamic therapy"},{"date":"2026","pmid":"41668835","title":"B-Cell Lymphoma Following an Indolent Course Over 30 Years with Immunophenotypic Changes at Each Recurrence.","journal":"European journal of case reports in internal medicine"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pinorubicin is a small molecule used in the treatment of various conditions, including Hepatocellular Carcinoma and Lymphoma, as per ClinicalTrials.gov. It is also known by other names, including Adriamycin and Pirarubicin, as listed in ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}